Archives of The Medicine and Case Reports
October 13, 2021
Andrian Fajar Kusumadewi
2 citations
Introduction. Psilocybe mushroom, or wi dely known as the magic mushroom is a variety of mushroom commonly consumed because of hallucinogenic traits it causes toward its consumer. This hallucinogenic effect is caused by Psilocybin, a hallucinogenic substance often found within Psilocybe mushroom. This substance affects mental state of the consumer and has similar effect to those of LSD and...
New England Journal of Medicine
April 14, 2021
Jeffrey A. Lieberman
18 citations
In The Doors of Perception, Aldous Huxley described his trial of mescaline as "the most extraordinary and significant experience available to human beings this side of the Beatific Vision." His exegesis was preceded by the synthesis of the hallucinogen lysergic acid diethylamide (LSD) by Sandoz chemist Albert Hoffman in 1938 and was followed by Hoffman's extraction of psilocybin from Psilocybe...
European Psychiatry
April 1, 2021
Jackelyne Gabrielle Jesus de Miranda, Mario Barbosa, I. Figueiredo et al.
Introduction Classic psychedelics have been administered in sacramental contexts since ancient times. They were of prominent interest within psychiatry and neuroscience in the 1950s to 1960s, but the association between classic psychedelics and the emerging counterculture put an end to their research. Modern research with classic psychedelics has reinitiated interest in the treatment of both...
European Psychiatry
April 1, 2021
Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al.
1 citation
Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the...
European Psychiatry
April 1, 2021
S. Torres
2 citations
Introduction Psychedelics - including LSD (lysergic acid diethylamide), psilocybin, DMT (N, N-dimethyltryptamine), ayahuasca and mescaline - have an ancient history across various civilizations. In 1950, after LSD’s discovery by Hofmann, psychedelics enjoyed a short-lived relationship with psychiatry, before prohibitive legislature emerging in response to the recreational use in the mid-1960s....
Frontiers in Pharmacology
January 20, 2021
Ole Jensen, Muhammad Rafehi, Lukas Gebauer et al.
24 citations
Psychostimulants are used therapeutically and for illegal recreational purposes. Many of these are inhibitors of the presynaptic noradrenaline, dopamine, and serotonin transporters (NET, DAT, and SERT). According to their physicochemical properties, some might also be substrates of polyspecific organic cation transporters (OCTs) that mediate uptake in liver and kidneys for metabolism and...
Pharmacopsychiatry
December 7, 2020
David E. Nichols, Hannes Walter
131 citations
Abstract Initial interest in the value of psychedelic drugs (“psychotomimetics”) in psychiatry began in the early 20th century, with explorations of the possibility that mescaline or peyote could produce psychosis-like effects. Over time, interest was focused on whether the effects of psychedelics could inform as to the underlying basis for psychiatric disorders. As research continued, and...
Journal of Neuroscience
November 30, 2020
Danilo de Gregorio, Argel Aguilar-Valles, Katrin H. Preller et al.
258 citations
A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of...
Yale University Press eBooks
October 27, 2020
Russell Crandall
This chapter focuses on psychedelics as another emerging front in the war over the war on drugs in the mid 2010s, with most psychedelic substances, such as LSD, mescaline, and psilocybin, being Schedule I listed since 1970. It explains how the scheduling imposed significant barriers to scientific research on hallucinogenic substances and their effects, through stringent security requirements,...
Journal of Neurology, Neurosurgery, and Psychiatry
July 20, 2020
Matthew Butler, Mathieu Seynaeve, Timothy R. Nicholson et al.
Aims Functional neurological disorder (FND), formerly known as conversion disorder, causes a high burden of disability and distress, and is amongst the most commonly encountered conditions in neurology clinics and neuropsychiatry services, yet the therapeutic evidence base is limited. Research into psychedelics such as psilocybin and lysergic acid diethylamide (LSD) is currently being...